Sickle Cell Disease Trial, Recruiting (NCT02098863)

Sickle Cell Disease Trial, Recruiting NCT02098863 Sponsor: St. Jude Children's Research Hospital Condition: Sickle Cell Disease

Printed from Voxsanity (voxsanity.com.au) — NCT02098863 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sickle Cell Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with sickle cell disease of any type.
(For the PK sub-study only) You are a patient at St. Jude Children's Research Hospital and have already joined the main study (SCCRIP, version 6.1 or later).
(For the PK sub-study only) You are currently taking hydroxyurea, have reached the highest dose that works safely for you, and have been on that dose for at least 90 days before joining.

Who may not be able to join:

The study doctors feel that, for any medical or personal reason, joining the study would not be in your best interest.
(For the PK sub-study only) You are unable to have the blood draws that are required for this part of the study.
(For the PK sub-study only) You, or your parent or legal guardian if applicable, are unwilling or unable to sign a written consent form to participate.
(For the PK sub-study only) The study doctors feel that, for any medical or personal reason, joining the sub-study would not be in your best interest.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Deepa Manwani, MD, St. Jude Children's Research Hospital

Phone: 888-226-4343

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT02098863

Sponsor: St. Jude Children's Research Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Sickle Cell Disease

Trial contact: 888-226-4343

More information: https://clinicaltrials.gov/study/NCT02098863

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with sickle cell disease of any type.
(For the PK sub-study only) You are a patient at St. Jude Children's Research Hospital and have already joined the main study (SCCRIP, version 6.1 or later).
(For the PK sub-study only) You are currently taking hydroxyurea, have reached the highest dose that works safely for you, and have been on that dose for at least 90 days before joining.

Who may not be able to join:

The study doctors feel that, for any medical or personal reason, joining the study would not be in your best interest.
(For the PK sub-study only) You are unable to have the blood draws that are required for this part of the study.
(For the PK sub-study only) You, or your parent or legal guardian if applicable, are unwilling or unable to sign a written consent form to participate.
(For the PK sub-study only) The study doctors feel that, for any medical or personal reason, joining the sub-study would not be in your best interest.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

St. Jude Children's Research Hospital

Registry

ClinicalTrials.gov

Start date

15 April 2014

Est. completion

1 December 2044

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Relationship between treatment plan and health outcomes in participants with sickle cell disease (SCD); Relationship between genetic properties of biological samples and health outcomes in participants with sickle cell disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov